Febrile neutropenia: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
mNo edit summary
 
(148 intermediate revisions by 6 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{| class="infobox" style="float:right;"
{{Siren|Febrile neutropenia}}
|-
{{Febrile neutropenia}}
| [[File:Siren.gif|30px|link=Febrile neutropenia resident survival guide]]|| <br> || <br>
| [[Febrile neutropenia resident survival guide|'''Resident'''<br>'''Survival'''<br>'''Guide''']]
|}
{{SI}}
{{CMG}}
{{CMG}}


{{SK}} FN, febrile leukopenia, neutropenic fever, neutropenic fever syndrome, neutropenic sepsis, hot and low, F and N, a hot leuk
{{SK}} F and N; fever and neutropenia; FN; hot and low; hot leuk; neutropenic fever; neutropenic fever syndrome; neutropenic sepsis


==Overview==
==[[Febrile neutropenia overview|Overview]]==
'''Febrile neutropenia''' is the development of [[fever]], often with other signs of [[infection]], in a patient with [[neutropenia]], an abnormally low number of [[neutrophil granulocyte]]s (a type of [[white blood cell]]) in the blood. The term '''neutropenic sepsis''' is also applied, although it tends to be reserved for patients who are less well. In 50% of cases, an infection is detectable; [[bacteremia]] (bacteria in the bloodstream) is present in approximately 20% of all patients with this condition.<ref name="pmid11850858">{{cite journal |author=Hughes WT, Armstrong D, Bodey GP, ''et al.'' |title=2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer |journal=Clin. Infect. Dis. |volume=34 |issue=6 |pages=730–51 |year=2002 |pmid=11850858 |doi=10.1086/339215| url=http://www.journals.uchicago.edu/doi/full/10.1086/339215 |month= March|issn=1058-4838}}</ref>


==Causes==
==[[Febrile neutropenia historical perspective|Historical Perspective]]==
* Febrile neutropenia can develop in any form of neutropenia, but is most generally recognized as a complication of [[chemotherapy]] when it is [[myelosuppressive]] (suppresses the [[bone marrow]] from producing blood cells).
* Medication induced:[[caspofungin acetate]], [[Cyclophosphamide]], [[Eribulin]], [[Nelarabine]], [[Pertuzumab]]


==Multinational Association for Supportive Care in Cancer (MASCC) Risk Index==
==[[Febrile neutropenia pathophysiology|Pathophysiology]]==
The Multinational Association for Supportive Care in Cancer (MASCC) Risk Index can be used to identify high-risk patients (score <21) and low-risk patients (score ≥21 points) for serious complications of febrile neutropenia (including death, [[intensive care unit]] admission, confusion, cardiac complications, [[respiratory failure]], [[renal failure]], [[hypotension]], [[bleeding]], and other serious medical complications).<ref name="pmid10944139">{{cite journal |author=Klastersky J, Paesmans M, Rubenstein EB, ''et al.'' |title=The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.|journal= J Clin Oncol. |volume=18 |issue=16 |pages=3038–51 |date=16 August 2000|pmid=10944139| url=http://jco.ascopubs.org/cgi/content/full/18/16/3038 |issn=0732-183X}}</ref>  The score was developed to select patients for therapeutic strategies that could potentially be more convenient or cost-effective.  The various variables and the weight of individual variables used in the MASCC risk index is as follows.  To summarize, risk assessment helps determining the type of empirical antibiotic therapy, venue of the treatment, and duration of the antibiotic therapy.


{|class="wikitable"
==[[Febrile neutropenia causes|Causes]]==
! Characteristic!! Score
|-
| No or mild symptoms in patients following an episode of febrile neutropenia || 5
|-
| Absence of hypotension with a systolic blood pressure >90 mmHg || 5
|-
| No chronic obstructive pulmonary disease (active chronic bronchitis, emphysema, decrease in forced expiratory volumes, need for oxygen therapy and/or steroids and/or bronchodilators) || 4
|-
| Solid tumor or hematologic malignancy with no previously demonstrated fungal infection or empirically treated suspected fungal infection|| 4
|-
| Absence of dehydration that requires parenteral fluids|| 3
|-
| Moderate symptoms in patients following an episode of febrile neutropenia|| 3
|-
| Outpatient status|| 3
|-
| Age <60 years|| 2
|-
|} 


A prospective trial demonstrated that a modified MASCC score can identify patients with febrile neutropenia at low risk of complications as well.<ref name="pmid17960431">{{cite journal |author=de Souza Viana L, Serufo JC, da Costa Rocha MO, Costa RN, Duarte RC |title=Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients |journal=Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer |volume=16 |issue=7 |pages=841–6 |year=2008 |month=July |pmid=17960431 |doi=10.1007/s00520-007-0347-3 |issn=0941-4355}}</ref>
==[[Febrile neutropenia epidemiology and demographics|Epidemiology and Demographics]]==


==Treatment==
==[[Febrile neutropenia risk factors|Risk Factors]]==
Generally, patients with febrile neutropenia are treated with empirical [[antibiotic]]s until the neutrophil count has recovered (Absolute neutrophil counts greater than 500/mm3) and the fever has abated; if the neutrophil count does not improve, treatment may need to continue for two weeks or occasionally more. In cases of recurrent or persistent fever, an antifungal agent should be added.


Guidelines issued in 2002 by the [[Infectious Diseases Society of America]] recommend the use of particular combinations of antibiotics in specific settings; mild low-risk cases may be treated with a combination of oral [[co-amoxiclav]] and [[ciprofloxacin]], while more severe cases require [[cephalosporin]]s with activity against ''[[Pseudomonas aeruginosa]]'' (e.g. [[cefepime]]), or [[carbapenem]]s ([[imipenem]] or [[meropenem]]).<ref name="pmid11850858"/> A subsequent [[meta-analysis]] published in 2006 found that [[cefepime]] was associated with more negative outcomes, and that carbapenems (while causing a higher rate of [[pseudomembranous colitis]]) were the most straightforward in use.<ref name="pmid16344285">{{cite journal |author=Paul M, Yahav D, Fraser A, Leibovici L |title=Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials |journal=J. Antimicrob. Chemother. |volume=57 |issue=2 |pages=176–89 |year=2006 |pmid=16344285 |doi=10.1093/jac/dki448|url=http://jac.oxfordjournals.org/cgi/content/full/57/2/176 |month= February|issn=0305-7453}}</ref>
==[[Febrile neutropenia natural history, complications and prognosis|Natural History, Complications and Prognosis]]==


In 2010, an updated guidelines was issued by the [[Infectious Diseases Society of America]], recommending use of cefepime, carbapenems (meropenem and imipenem/cilastatin), piperacillin/tazobactam for high risk patients and [[co-amoxiclav]] and [[ciprofloxacin]] for low risk patients. Patients who do not strictly fulfill the criteria of 'low risk patients' should be admitted to the hospital and treat as high risk patients.
==Diagnosis==
[[Febrile neutropenia diagnostic criteria|Diagnostic Criteria]] | [[Febrile neutropenia initial assessment|Initial Assessment]] | [[Febrile neutropenia history and symptoms|History and Symptoms]] | [[Febrile neutropenia physical examination|Physical Examination]] | [[Febrile neutropenia laboratory findings|Laboratory Findings]] | [[Febrile neutropenia CT|CT]] | [[Febrile neutropenia other diagnostic studies|Other Diagnostic Studies]]


==See also==
== Treatment ==
*[[Neutropenia]]
[[Febrile neutropenia medical therapy|Medical Therapy]] | [[Febrile neutropenia primary prevention|Primary Prevention]]
*[[Leukocytopenia]]
 
== Guideline Sources ==
* Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America<ref>{{Cite journal | doi = 10.1093/cid/ciq147 | issn = 1537-6591 | volume = 52 | issue = 4 | pages = 427–431 | last = Freifeld | first = Alison G. | coauthors = Eric J. Bow, Kent A. Sepkowitz, Michael J. Boeckh, James I. Ito, Craig A. Mullen, Issam I. Raad, Kenneth V. Rolston, Jo-Anne H. Young, John R. Wingard, null Infectious Diseases Society of Americaa | title = Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America | journal = Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America | date = 2011-02-15 | pmid = 21205990 }}</ref>
 
* Antimicrobial Prophylaxis and Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology Clinical Practice Guideline<ref>{{Cite journal | doi = 10.1200/JCO.2012.45.8661 | issn = 1527-7755 | volume = 31 | issue = 6 | pages = 794–810 | last = Flowers | first = Christopher R. | coauthors = Jerome Seidenfeld, Eric J. Bow, Clare Karten, Charise Gleason, Douglas K. Hawley, Nicole M. Kuderer, Amelia A. Langston, Kieren A. Marr, Kenneth V. I. Rolston, Scott D. Ramsey | title = Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline | journal = Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology | date = 2013-02-20 | pmid = 23319691 }}</ref>
 
* Guideline for the Management of Fever and Neutropenia in Children with Cancer and/or Undergoing Hematopoietic Stem-Cell Transplantation: American Society of Clinical Oncology Endorsement<ref>{{Cite journal | doi = 10.1200/JCO.2012.42.7161 | issn = 1527-7755 | volume = 30 | issue = 35 | pages = 4427–4438 | last = Lehrnbecher | first = Thomas | coauthors = Robert Phillips, Sarah Alexander, Frank Alvaro, Fabianne Carlesse, Brian Fisher, Hana Hakim, Maria Santolaya, Elio Castagnola, Bonnie L. Davis, L. Lee Dupuis, Faith Gibson, Andreas H. Groll, Aditya Gaur, Ajay Gupta, Rejin Kebudi, Sérgio Petrilli, William J. Steinbach, Milena Villarroel, Theoklis Zaoutis, Lillian Sung, International Pediatric Fever and Neutropenia Guideline Panel | title = Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation | journal = Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology | date = 2012-12-10 | pmid = 22987086 }}</ref>
 
* Prevention and Treatment of Cancer-Related Infections: National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology<ref>{{Cite web | title =  Prevention and Treatment of Cancer-Related Infections | accessdate =  | url = http://www.nccn.org/professionals/physician_gls/PDF/infections.pdf }}</ref>
 
* Management of Febrile Neutropenia: European Society for Medical Oncology Clinical Recommendations<ref>{{Cite journal | doi = 10.1093/annonc/mdp163 | issn = 1569-8041 | volume = 20 Suppl 4 | pages = 166–169 | last = Marti | first = F. Marti | coauthors = M. H. Cullen, F. Roila, ESMO Guidelines Working Group | title = Management of febrile neutropenia: ESMO clinical recommendations | journal = Annals of oncology: official journal of the European Society for Medical Oncology / ESMO | date = 2009-05 | pmid = 19454445 }}</ref>
 
== References ==
{{reflist|2}}
 
== Related Chapters ==
*[[Chemotherapy]]
*[[Fever]]
*[[Fever]]
*[[Leukopenia]]
*[[Myelosuppression]]
*[[Myelosuppression]]
*[[Chemotherapy]]
*[[Neutropenia]]
 
==References==
{{Reflist|2}}


==External links==
== External Links ==
* [http://www.cancer.gov/dictionary?CdrID=415543 Febrile neutropenia] entry in the public domain NCI Dictionary of Cancer Terms
* [http://www.cancer.gov/dictionary?CdrID=415543 Febrile neutropenia entry in the NCI Dictionary of Cancer Terms]

Latest revision as of 23:28, 3 April 2015

Resident
Survival
Guide

Febrile Neutropenia Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

Initial Assessment

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Febrile neutropenia On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Febrile neutropenia

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Febrile neutropenia

CDC on Febrile neutropenia

Febrile neutropenia in the news

Blogs on Febrile neutropenia

Directions to Hospitals Treating Febrile neutropenia

Risk calculators and risk factors for Febrile neutropenia

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and keywords: F and N; fever and neutropenia; FN; hot and low; hot leuk; neutropenic fever; neutropenic fever syndrome; neutropenic sepsis

Overview

Historical Perspective

Pathophysiology

Causes

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria | Initial Assessment | History and Symptoms | Physical Examination | Laboratory Findings | CT | Other Diagnostic Studies

Treatment

Medical Therapy | Primary Prevention

Guideline Sources

  • Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America[1]
  • Antimicrobial Prophylaxis and Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology Clinical Practice Guideline[2]
  • Guideline for the Management of Fever and Neutropenia in Children with Cancer and/or Undergoing Hematopoietic Stem-Cell Transplantation: American Society of Clinical Oncology Endorsement[3]
  • Prevention and Treatment of Cancer-Related Infections: National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology[4]
  • Management of Febrile Neutropenia: European Society for Medical Oncology Clinical Recommendations[5]

References

  1. ↑ Freifeld, Alison G. (2011-02-15). "Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America". Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 52 (4): 427–431. doi:10.1093/cid/ciq147. ISSN 1537-6591. PMID 21205990. Unknown parameter |coauthors= ignored (help)
  2. ↑ Flowers, Christopher R. (2013-02-20). "Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline". Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 31 (6): 794–810. doi:10.1200/JCO.2012.45.8661. ISSN 1527-7755. PMID 23319691. Unknown parameter |coauthors= ignored (help)
  3. ↑ Lehrnbecher, Thomas (2012-12-10). "Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation". Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 30 (35): 4427–4438. doi:10.1200/JCO.2012.42.7161. ISSN 1527-7755. PMID 22987086. Unknown parameter |coauthors= ignored (help)
  4. ↑ "Prevention and Treatment of Cancer-Related Infections" (PDF).
  5. ↑ Marti, F. Marti (2009-05). "Management of febrile neutropenia: ESMO clinical recommendations". Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 20 Suppl 4: 166–169. doi:10.1093/annonc/mdp163. ISSN 1569-8041. PMID 19454445. Unknown parameter |coauthors= ignored (help); Check date values in: |date= (help)

Related Chapters

External Links

Retrieved from "https://www.wikidoc.org/index.php?title=Febrile_neutropenia&oldid=1082624"